Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
ATF6 [corrected] and thrombospondin 4: the dynamic duo of the adaptive endoplasmic reticulum stress response.

Circulation research

Doroudgar S, Glembotski CC.
PMID: 23287452
Circ Res. 2013 Jan 04;112(1):9-12. doi: 10.1161/CIRCRESAHA.112.280560.

No abstract available.

Cite
Doroudgar S, Glembotski CC. ATF6 [corrected] and thrombospondin 4: the dynamic duo of the adaptive endoplasmic reticulum stress response. Circ Res. 2013;112(1):9-12doi: 10.1161/CIRCRESAHA.112.280560.
Doroudgar, S., & Glembotski, C. C. (2013). ATF6 [corrected] and thrombospondin 4: the dynamic duo of the adaptive endoplasmic reticulum stress response. Circulation research, 112(1), 9-12. https://doi.org/10.1161/CIRCRESAHA.112.280560
Doroudgar, Shirin, and Glembotski, Christopher C. "ATF6 [corrected] and thrombospondin 4: the dynamic duo of the adaptive endoplasmic reticulum stress response." Circulation research vol. 112,1 (2013): 9-12. doi: https://doi.org/10.1161/CIRCRESAHA.112.280560
Doroudgar S, Glembotski CC. ATF6 [corrected] and thrombospondin 4: the dynamic duo of the adaptive endoplasmic reticulum stress response. Circ Res. 2013 Jan 04;112(1):9-12. doi: 10.1161/CIRCRESAHA.112.280560. PMID: 23287452; PMCID: PMC3711712.
Copy Download .nbib Format: NLM
Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia.

Scientific reports

Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, Montero VS, Rabinovich GA, Molinas FC, Heller PG, Lev PR, Marta RF.
PMID: 30778108
Sci Rep. 2019 Feb 18;9(1):2208. doi: 10.1038/s41598-018-38086-1.

Mechanisms leading to low platelet count in immune thrombocytopenia (ITP) involves both decreased production and increased destruction of platelet. However, the contribution of these pathologic mechanisms to clinical outcome of individual patients is uncertain. Here we evaluated different pathogenic...

Cite
Grodzielski M, Goette NP, Glembotsky AC, et al. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep. 2019;9(1):2208doi: 10.1038/s41598-018-38086-1.
Grodzielski, M., Goette, N. P., Glembotsky, A. C., Constanza Baroni Pietto, M., Méndez-Huergo, S. P., Pierdominici, M. S., Montero, V. S., Rabinovich, G. A., Molinas, F. C., Heller, P. G., Lev, P. R., & Marta, R. F. (2019). Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Scientific reports, 9(1), 2208. https://doi.org/10.1038/s41598-018-38086-1
Grodzielski, Matías, et al. "Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia." Scientific reports vol. 9,1 (2019): 2208. doi: https://doi.org/10.1038/s41598-018-38086-1
Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, Montero VS, Rabinovich GA, Molinas FC, Heller PG, Lev PR, Marta RF. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep. 2019 Feb 18;9(1):2208. doi: 10.1038/s41598-018-38086-1. PMID: 30778108; PMCID: PMC6379541.
Copy Download .nbib Format: NLM
Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia.

Scientific reports

Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, Montero VS, Rabinovich GA, Molinas FC, Heller PG, Lev PR, Marta RF.
PMID: 32051428
Sci Rep. 2020 Feb 12;10(1):2787. doi: 10.1038/s41598-020-58553-y.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Grodzielski M, Goette NP, Glembotsky AC, et al. Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep. 2020;10(1):2787doi: 10.1038/s41598-020-58553-y.
Grodzielski, M., Goette, N. P., Glembotsky, A. C., Constanza Baroni Pietto, M., Méndez-Huergo, S. P., Pierdominici, M. S., Montero, V. S., Rabinovich, G. A., Molinas, F. C., Heller, P. G., Lev, P. R., & Marta, R. F. (2020). Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Scientific reports, 10(1), 2787. https://doi.org/10.1038/s41598-020-58553-y
Grodzielski, Matías, et al. "Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia." Scientific reports vol. 10,1 (2020): 2787. doi: https://doi.org/10.1038/s41598-020-58553-y
Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, Montero VS, Rabinovich GA, Molinas FC, Heller PG, Lev PR, Marta RF. Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep. 2020 Feb 12;10(1):2787. doi: 10.1038/s41598-020-58553-y. PMID: 32051428; PMCID: PMC7015908.
Copy Download .nbib Format: NLM
Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus.

Platelets

Baroni Pietto MC, Lev PR, Glembotsky AC, Marín Oyarzún CP, Gomez G, Collado V, Pisoni C, Gomez RA, Grodzielski M, Gonzalez J, Mariño KV, Heller PG, Goette NP, Marta RF.
PMID: 34806522
Platelets. 2021 Nov 21;1-12. doi: 10.1080/09537104.2021.1988547. Epub 2021 Nov 21.

SummarySystemic lupus erythematosus (SLE) is an autoimmune condition developing thrombocytopenia in about 10-15% of cases, however, mechanisms leading to low platelet count were not deeply investigated in this illness. Here we studied possible causes of thrombocytopenia, including different mechanisms...

Cite
Baroni Pietto MC, Lev PR, Glembotsky AC, et al. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus. Platelets. 2021;1-12doi: 10.1080/09537104.2021.1988547.
Baroni Pietto, M. C., Lev, P. R., Glembotsky, A. C., Marín Oyarzún, C. P., Gomez, G., Collado, V., Pisoni, C., Gomez, R. A., Grodzielski, M., Gonzalez, J., Mariño, K. V., Heller, P. G., Goette, N. P., & Marta, R. F. (2021). Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus. Platelets, 1-12. https://doi.org/10.1080/09537104.2021.1988547
Baroni Pietto, M Constanza, et al. "Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus." Platelets vol. (2021): 1-12. doi: https://doi.org/10.1080/09537104.2021.1988547
Baroni Pietto MC, Lev PR, Glembotsky AC, Marín Oyarzún CP, Gomez G, Collado V, Pisoni C, Gomez RA, Grodzielski M, Gonzalez J, Mariño KV, Heller PG, Goette NP, Marta RF. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus. Platelets. 2021 Nov 21;1-12. doi: 10.1080/09537104.2021.1988547. Epub 2021 Nov 21. PMID: 34806522.
Copy Download .nbib Format: NLM
Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury.

ACS medicinal chemistry letters

Palmer JE, Brietske BM, Bate TC, Blackwood EA, Garg M, Glembotski CC, Cooley CB.
PMID: 32184959
ACS Med Chem Lett. 2019 Nov 06;11(3):292-297. doi: 10.1021/acsmedchemlett.9b00299. eCollection 2020 Mar 12.

We describe here the design, synthesis, and biological evaluation of a reactive oxygen species (ROS)-activatable prodrug for the selective delivery of

Cite
Palmer JE, Brietske BM, Bate TC, et al. Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury. ACS Med Chem Lett. 2019;11(3):292-297doi: 10.1021/acsmedchemlett.9b00299.
Palmer, J. E., Brietske, B. M., Bate, T. C., Blackwood, E. A., Garg, M., Glembotski, C. C., & Cooley, C. B. (2020). Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury. ACS medicinal chemistry letters, 11(3), 292-297. https://doi.org/10.1021/acsmedchemlett.9b00299
Palmer, Jonathan E, et al. "Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury." ACS medicinal chemistry letters vol. 11,3 (2020): 292-297. doi: https://doi.org/10.1021/acsmedchemlett.9b00299
Palmer JE, Brietske BM, Bate TC, Blackwood EA, Garg M, Glembotski CC, Cooley CB. Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury. ACS Med Chem Lett. 2019 Nov 06;11(3):292-297. doi: 10.1021/acsmedchemlett.9b00299. eCollection 2020 Mar 12. PMID: 32184959; PMCID: PMC7073885.
Copy Download .nbib Format: NLM
A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.

Journal of blood medicine

Glembotsky AC, De Luca G, Heller PG.
PMID: 34408521
J Blood Med. 2021 Aug 11;12:719-732. doi: 10.2147/JBM.S270018. eCollection 2021.

The gray platelet syndrome (GPS) is a rare platelet disorder, characterized by impaired alpha-granule biogenesis in megakaryocytes and platelets due to NBEAL2 mutations. Typical clinical features include macrothrombocytopenia, bleeding and elevated vitamin B12 levels, while bone marrow fibrosis and...

Cite
Glembotsky AC, De Luca G, Heller PG. A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation. J Blood Med. 2021;12:719-732doi: 10.2147/JBM.S270018.
Glembotsky, A. C., De Luca, G., & Heller, P. G. (2021). A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation. Journal of blood medicine, 12719-732. https://doi.org/10.2147/JBM.S270018
Glembotsky, Ana C, et al. "A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation." Journal of blood medicine vol. 12 (2021): 719-732. doi: https://doi.org/10.2147/JBM.S270018
Glembotsky AC, De Luca G, Heller PG. A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation. J Blood Med. 2021 Aug 11;12:719-732. doi: 10.2147/JBM.S270018. eCollection 2021. PMID: 34408521; PMCID: PMC8364843.
Copy Download .nbib Format: NLM
ATF6 as a Nodal Regulator of Proteostasis in the Heart.

Frontiers in physiology

Glembotski CC, Arrieta A, Blackwood EA, Stauffer WT.
PMID: 32322217
Front Physiol. 2020 Apr 08;11:267. doi: 10.3389/fphys.2020.00267. eCollection 2020.

Proteostasis encompasses a homeostatic cellular network in all cells that maintains the integrity of the proteome, which is critical for optimal cellular function. The components of the proteostasis network include protein synthesis, folding, trafficking, and degradation. Cardiac myocytes have...

Cite
Glembotski CC, Arrieta A, Blackwood EA, et al. ATF6 as a Nodal Regulator of Proteostasis in the Heart. Front Physiol. 2020;11:267doi: 10.3389/fphys.2020.00267.
Glembotski, C. C., Arrieta, A., Blackwood, E. A., & Stauffer, W. T. (2020). ATF6 as a Nodal Regulator of Proteostasis in the Heart. Frontiers in physiology, 11267. https://doi.org/10.3389/fphys.2020.00267
Glembotski, Christopher C, et al. "ATF6 as a Nodal Regulator of Proteostasis in the Heart." Frontiers in physiology vol. 11 (2020): 267. doi: https://doi.org/10.3389/fphys.2020.00267
Glembotski CC, Arrieta A, Blackwood EA, Stauffer WT. ATF6 as a Nodal Regulator of Proteostasis in the Heart. Front Physiol. 2020 Apr 08;11:267. doi: 10.3389/fphys.2020.00267. eCollection 2020. PMID: 32322217; PMCID: PMC7156617.
Copy Download .nbib Format: NLM
Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation.

Circulation

Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC, Master A, Cheryan S.
PMID: 33999662
Circulation. 2021 May 18;143(20):2025-2027. doi: 10.1161/CIRCULATIONAHA.120.052437. Epub 2021 May 17.

No abstract available.

Cite
Bilal AS, Blackwood EA, Thuerauf DJ, et al. Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation. 2021;143(20):2025-2027doi: 10.1161/CIRCULATIONAHA.120.052437.
Bilal, A. S., Blackwood, E. A., Thuerauf, D. J., Glembotski, C. C., Master, A., & Cheryan, S. (2021). Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation, 143(20), 2025-2027. https://doi.org/10.1161/CIRCULATIONAHA.120.052437
Bilal, Alina S, et al. "Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation." Circulation vol. 143,20 (2021): 2025-2027. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.052437
Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC, Master A, Cheryan S. Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation. 2021 May 18;143(20):2025-2027. doi: 10.1161/CIRCULATIONAHA.120.052437. Epub 2021 May 17. PMID: 33999662; PMCID: PMC8529561.
Copy Download .nbib Format: NLM
Integrating ER and Mitochondrial Proteostasis in the Healthy and Diseased Heart.

Frontiers in cardiovascular medicine

Arrieta A, Blackwood EA, Stauffer WT, Glembotski CC.
PMID: 32010709
Front Cardiovasc Med. 2020 Jan 15;6:193. doi: 10.3389/fcvm.2019.00193. eCollection 2019.

The integrity of the proteome in cardiac myocytes is critical for robust heart function. Proteome integrity in all cells is managed by protein homeostasis or proteostasis, which encompasses processes that maintain the balance of protein synthesis, folding, and degradation...

Cite
Arrieta A, Blackwood EA, Stauffer WT, et al. Integrating ER and Mitochondrial Proteostasis in the Healthy and Diseased Heart. Front Cardiovasc Med. 2020;6:193doi: 10.3389/fcvm.2019.00193.
Arrieta, A., Blackwood, E. A., Stauffer, W. T., & Glembotski, C. C. (2019). Integrating ER and Mitochondrial Proteostasis in the Healthy and Diseased Heart. Frontiers in cardiovascular medicine, 6193. https://doi.org/10.3389/fcvm.2019.00193
Arrieta, Adrian, et al. "Integrating ER and Mitochondrial Proteostasis in the Healthy and Diseased Heart." Frontiers in cardiovascular medicine vol. 6 (2019): 193. doi: https://doi.org/10.3389/fcvm.2019.00193
Arrieta A, Blackwood EA, Stauffer WT, Glembotski CC. Integrating ER and Mitochondrial Proteostasis in the Healthy and Diseased Heart. Front Cardiovasc Med. 2020 Jan 15;6:193. doi: 10.3389/fcvm.2019.00193. eCollection 2019. PMID: 32010709; PMCID: PMC6974444.
Copy Download .nbib Format: NLM
Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients.

Scientific reports

Di Buduo CA, Alberelli MA, Glembotsky AC, Podda G, Lev PR, Cattaneo M, Landolfi R, Heller PG, Balduini A, De Candia E.
PMID: 27126656
Sci Rep. 2016 Apr 29;6:25027. doi: 10.1038/srep25027.

No abstract available.

Cite
Di Buduo CA, Alberelli MA, Glembotsky AC, et al. Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients. Sci Rep. 2016;6:25027doi: 10.1038/srep25027.
Di Buduo, C. A., Alberelli, M. A., Glembotsky, A. C., Podda, G., Lev, P. R., Cattaneo, M., Landolfi, R., Heller, P. G., Balduini, A., & De Candia, E. (2016). Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients. Scientific reports, 625027. https://doi.org/10.1038/srep25027
Di Buduo, Christian A, et al. "Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients." Scientific reports vol. 6 (2016): 25027. doi: https://doi.org/10.1038/srep25027
Di Buduo CA, Alberelli MA, Glembotsky AC, Podda G, Lev PR, Cattaneo M, Landolfi R, Heller PG, Balduini A, De Candia E. Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients. Sci Rep. 2016 Apr 29;6:25027. doi: 10.1038/srep25027. PMID: 27126656; PMCID: PMC4850441.
Copy Download .nbib Format: NLM
Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation.

Circulation

Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC.
PMID: 33999662
Circulation. 2021 May 18;143(20):2025-2027. doi: 10.1161/CIRCULATIONAHA.120.052437. Epub 2021 May 17.

No abstract available.

Cite
Bilal AS, Blackwood EA, Thuerauf DJ, et al. Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation. 2021;143(20):2025-2027doi: 10.1161/CIRCULATIONAHA.120.052437.
Bilal, A. S., Blackwood, E. A., Thuerauf, D. J., & Glembotski, C. C. (2021). Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation, 143(20), 2025-2027. https://doi.org/10.1161/CIRCULATIONAHA.120.052437
Bilal, Alina S, et al. "Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation." Circulation vol. 143,20 (2021): 2025-2027. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.052437
Bilal AS, Blackwood EA, Thuerauf DJ, Glembotski CC. Optimizing Adeno-Associated Virus Serotype 9 for Studies of Cardiac Chamber-Specific Gene Regulation. Circulation. 2021 May 18;143(20):2025-2027. doi: 10.1161/CIRCULATIONAHA.120.052437. Epub 2021 May 17. PMID: 33999662; PMCID: PMC8529561.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries